Mark  Gustafson net worth and biography

Mark Gustafson Biography and Net Worth

Director of Alzamend Neuro
Mark Gustafson joined our Board of Directors in June 2021 and is Chairman of the Audit Committee. Mr. Gustafson is a Chartered Professional Accountant with over 35 years of corporate, private and public company experience. Since April 2021, Mr. Gustafson has been the Chief Financial Officer for PharmaKure Limited, a London-based biopharmaceutical company dedicated to the treatment of neurodegenerative diseases. From 2014 to 2020, he was the Chief Executive Officer of Challenger Acquisitions Limited, a London Stock Exchange listed entertainment company. From 2010 to 2012, Mr. Gustafson was the President and Chief Executive Officer of Euromax Resources Limited, a Toronto Stock Exchange listed mineral exploration company. From 2005 to 2009, he served as Chairman and Chief Executive Officer of Triangle Energy Corporation, a New York Stock Exchange listed oil and gas exploration company, from 2004 to 2006, he served as President and Chief Executive Officer of Torrent Energy Corporation, a private oil and gas company, and from 2001 to 2002, he served as a financial consultant for Samson Oil & Gas and Peavine Resources, two private oil and gas companies. From 1997 to 1999, Mr. Gustafson served as President and Chief Executive Officer of Total Energy Services Ltd., a Toronto Stock Exchange listed oilfield services company, from 1993 to 1995, he served as the Chief Financial Officer of Q/media Software Corporation, a Toronto Stock Exchange listed software company, and from 1987 to 1993, he served initially as the Chief Financial Officer and then as a Vice President in charge of two operating divisions at EnServ Corporation, a Toronto Stock Exchange listed oilfield services company. From 1981 to 1987, he served as an audit manager at Price Waterhouse in Calgary Alberta. Mr. Gustafson received his Bachelor of Business Administration from Wilfrid Laurier University.

What is Mark Gustafson's net worth?

The estimated net worth of Mark Gustafson is at least $516.00 as of March 31st, 2022. Mr. Gustafson owns 400 shares of Alzamend Neuro stock worth more than $516 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Gustafson may own. Learn More about Mark Gustafson's net worth.

How do I contact Mark Gustafson?

The corporate mailing address for Mr. Gustafson and other Alzamend Neuro executives is , , . Alzamend Neuro can also be reached via phone at 844-722-6303. Learn More on Mark Gustafson's contact information.

Has Mark Gustafson been buying or selling shares of Alzamend Neuro?

Mark Gustafson has not been actively trading shares of Alzamend Neuro within the last three months. Most recently, Mark Gustafson sold 133 shares of the business's stock in a transaction on Thursday, March 31st. The shares were sold at an average price of $181.50, for a transaction totalling $24,139.50. Following the completion of the sale, the director now directly owns 400 shares of the company's stock, valued at $72,600. Learn More on Mark Gustafson's trading history.

Who are Alzamend Neuro's active insiders?

Alzamend Neuro's insider roster includes Milton Ault III (Major Shareholder), Milton Ault, III (Major Shareholder), Milton Ault, III. (Major Shareholder), Mark Gustafson (Director), and L. Smith (Insider). Learn More on Alzamend Neuro's active insiders.

Are insiders buying or selling shares of Alzamend Neuro?

During the last year, Alzamend Neuro insiders bought shares 7 times. They purchased a total of 803 shares worth more than $7,024.05. The most recent insider tranaction occured on August, 6th when Director Milton C Ault III bought 75 shares worth more than $206.25. Insiders at Alzamend Neuro own 10.6% of the company. Learn More about insider trades at Alzamend Neuro.

Information on this page was last updated on 8/6/2024.

Mark Gustafson Insider Trading History at Alzamend Neuro

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/31/2022Sell133$181.50$24,139.50400View SEC Filing Icon  
12/14/2021Sell133$427.50$56,857.50View SEC Filing Icon  
See Full Table

Mark Gustafson Buying and Selling Activity at Alzamend Neuro

This chart shows Mark Gustafson's buying and selling at Alzamend Neuro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alzamend Neuro Company Overview

Alzamend Neuro logo
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Read More

Today's Range

Now: $1.30
Low: $1.27
High: $1.32

50 Day Range

MA: $1.60
Low: $1.30
High: $1.93

2 Week Range

Now: $1.30
Low: $1.25
High: $15.06

Volume

132,012 shs

Average Volume

510,774 shs

Market Capitalization

$5.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A